BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Berenberg Bank. They set a "buy" rating and a $130.00 price target on the stock.
BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $125.00 price target on the stock, up previously from $110.00.
BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.
BioNTech to Acquire Biotheus to Boost Oncology Strategy